Andrew Hill Investment Advisors Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Andrew Hill Investment Advisors Inc. acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,262 shares of the pharmaceutical company’s stock, valued at approximately $4,989,000. Vertex Pharmaceuticals comprises approximately 5.2% of Andrew Hill Investment Advisors Inc.’s investment portfolio, making the stock its 2nd largest position.

Several other institutional investors have also modified their holdings of the stock. Venturi Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after purchasing an additional 24 shares during the last quarter. Arthur M. Cohen & Associates LLC lifted its stake in shares of Vertex Pharmaceuticals by 3.2% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after acquiring an additional 25 shares during the last quarter. Baystate Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 25 shares during the last quarter. Cooper Financial Group lifted its stake in shares of Vertex Pharmaceuticals by 1.0% during the 3rd quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock worth $1,050,000 after acquiring an additional 29 shares during the last quarter. Finally, Arjuna Capital lifted its stake in shares of Vertex Pharmaceuticals by 0.7% during the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after acquiring an additional 29 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the transaction, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the transaction, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 in the last quarter. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 0.2 %

VRTX stock traded up $0.80 on Friday, hitting $394.28. 429,574 shares of the company’s stock were exchanged, compared to its average volume of 1,233,885. Vertex Pharmaceuticals Incorporated has a 12-month low of $316.43 and a 12-month high of $448.40. The firm has a 50 day moving average price of $414.17 and a two-hundred day moving average price of $396.74. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The stock has a market cap of $101.91 billion, a P/E ratio of 28.33, a price-to-earnings-growth ratio of 1.85 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the firm posted $3.33 EPS. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VRTX. Oppenheimer reissued an “outperform” rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target for the company. in a research note on Wednesday, January 31st. UBS Group decreased their target price on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday. Truist Financial lifted their target price on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Wolfe Research initiated coverage on Vertex Pharmaceuticals in a research report on Thursday, February 15th. They set an “outperform” rating and a $515.00 target price for the company. Three research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.